EXELIXIS Reports 12% Increase in Q2 Revenue for FY2023 at USD 469.9 Million
August 13, 2023
☀️Earnings Overview
Exelixis ($NASDAQ:EXEL) announced that their total revenue for the second quarter of FY 2023, ending June 30, 2023, was USD 469.9 million, which is a 12.0% increase from the same quarter in the previous year. Net income also increased 14.9%, amounting to USD 81.2 million compared to the same period in the year prior.
Analysis
GoodWhale has conducted an analysis of EXELIXIS‘s fundamentals and the results are in! According to Risk Rating, EXELIXIS is a low risk investment in terms of financial and business aspects. While the overall rating is positive, GoodWhale has detected one risk warning in the income sheet. If you want to find out more, you need to become a registered user. GoodWhale’s analysis gives you a comprehensive overview of EXELIXIS’s financial performance. You can check out the company’s financial statements, asset ratios, liquidity indicators, and profitability ratios. Additionally, you can get insights into the company’s macroeconomic environment and industry trends. This helps you make informed decisions about your investments in EXELIXIS. So if you’re looking for a low risk investment with potential for growth, EXELIXIS could be the right choice for you. With GoodWhale’s detailed analysis, you can easily assess whether or not this stock is right for you. Become a registered user today and find out more about EXELIXIS’s fundamentals! More…
About the Company
Income Snapshot
Below shows the total revenue, net income and net margin for Exelixis. EXELIXIS_Reports_12_Increase_in_Q2_Revenue_for_FY2023_at_USD_469.9_Million”>More…
| Total Revenues | Net Income | Net Margin |
| 1.71k | 164.24 | 9.6% |
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Exelixis. EXELIXIS_Reports_12_Increase_in_Q2_Revenue_for_FY2023_at_USD_469.9_Million”>More…
| Operations | Investing | Financing |
| 389.15 | -438.11 | -124.25 |
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Exelixis. EXELIXIS_Reports_12_Increase_in_Q2_Revenue_for_FY2023_at_USD_469.9_Million”>More…
| Total Assets | Total Liabilities | Book Value Per Share |
| 3.14k | 614.53 | 7.89 |
Key Ratios Snapshot
Some of the financial key ratios for Exelixis are shown below. EXELIXIS_Reports_12_Increase_in_Q2_Revenue_for_FY2023_at_USD_469.9_Million”>More…
| 3Y Rev Growth | 3Y Operating Profit Growth | Operating Margin |
| 19.7% | -24.0% | 8.2% |
| FCF Margin | ROE | ROA |
| 12.4% | 3.5% | 2.8% |
Peers
Exelixis Inc is a biopharmaceutical company that focuses on the discovery, development, and commercialization of new therapies to treat cancer and other serious diseases. The company has a strong focus on research and development, and has a number of ongoing clinical trials for its potential treatments. Exelixis is up against some stiff competition from other companies in the same field, including Xeris Biopharma Holdings Inc, Freeline Therapeutics Holdings PLC, and TScan Therapeutics Inc.
– Xeris Biopharma Holdings Inc ($NASDAQ:XERS)
Xeris Biopharma Holdings Inc is a pharmaceutical company that focuses on the development and commercialization of therapies for the treatment of rare and orphan diseases. The company’s market cap as of 2022 is 176.74M. The company’s ROE is -148.11%. The company has a portfolio of products in various stages of development, including two products that are commercially available.
– Freeline Therapeutics Holdings PLC ($NASDAQ:FRLN)
Freeline Therapeutics Holdings PLC is a clinical-stage biopharmaceutical company focused on developing gene therapies for chronic liver diseases. The company’s lead product candidate, FLT-180a, is in development for the treatment of hemophilia B. Freeline Therapeutics Holdings PLC has a market cap of 44.18M as of 2022, a Return on Equity of -1.18%.
– TScan Therapeutics Inc ($NASDAQ:TCRX)
TScan Therapeutics Inc is a biotechnology company that focuses on the development of immunotherapies for the treatment of cancer. The company has a market cap of 77.27M as of 2022 and a return on equity of -44.32%. The company’s products are designed to harness the power of the immune system to target and kill cancer cells. The company’s products are currently in clinical trials and have shown promising results in the treatment of various types of cancer.
Summary
Exelixis, Inc. (NASDAQ: EXEL) reported strong financial results for its second quarter of fiscal year 2023, ending June 30th. Total revenue increased by 12.0% year-over-year to $469.9 million, while net income grew 14.9% to $81.2 million compared to the same quarter in 2023. This indicates that the company has been able to successfully manage its financial performance and continue to grow its business despite the challenging conditions caused by the global pandemic.
Investing in Exelixis could be a good option for investors looking to capitalize on this impressive growth. The company’s strong financial performance combined with favorable market conditions suggest that now may be a good time to invest in Exelixis.
Related Posts
Recent Posts
